Imbria_Logo_Colour.png
Imbria to Present Results from Phase 2 IMPROVE-ISCHEMIA Trial of Ninerafaxstat in Patients with Angina and Chronic Coronary Syndrome at the European Society of Cardiology Congress 2024
30. August 2024 08:00 ET | Imbria Pharmaceuticals Inc.
– Ninerafaxstat was well tolerated and showed no impact on systemic hemodynamics in patients with stable angina and chronic coronary syndrome – – These findings support a direct,...
Imbria_Logo_Colour.png
Imbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina
16. August 2023 08:00 ET | Imbria Pharmaceuticals Inc.
– IMPROVE-ISCHEMIA, a randomized, placebo-controlled trial, with topline data expected in 4Q 2023 – – Additional Phase 2 data read-outs expected in 4Q 2023, including topline from the IMPROVE-HCM...
Imbria_Logo_Colour.png
Imbria Pharmaceuticals Completes Enrollment in Phase 2 IMPROVE-HCM Trial of Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy
05. Juni 2023 08:00 ET | Imbria Pharmaceuticals Inc.
– Enrollment exceeded expectations, thus highlighting the large unmet need in non-obstructive hypertrophic cardiomyopathy – – IMPROVE-HCM topline data expected in 4Q 2023 – – Topline Phase 2 data...
Imbria_Logo_Colour.png
Imbria Enrolls First Patient in the Phase 2 IMPROVE-DiCE Clinical Trial Evaluating Ninerafaxstat in Patients with Heart Failure with Preserved Ejection Fraction
09. Januar 2023 08:00 ET | Imbria Pharmaceuticals Inc.
BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...
Imbria_Logo_Colour.png
Ninerafaxstat Showcased at the 19th Annual Global Cardio Vascular Clinical Trialists (CVCT) Forum with Focus on the Potential in Non-obstructive Hypertrophic Cardiomyopathy
05. Dezember 2022 08:00 ET | Imbria Pharmaceuticals Inc.
BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...